NASDAQ:ASBP Aspire Biopharma (ASBP) Stock Price, News & Analysis $5.43 -0.10 (-1.77%) As of 02:09 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aspire Biopharma Stock (NASDAQ:ASBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aspire Biopharma alerts:Sign Up Key Stats Today's Range$5.32▼$5.7750-Day Range$0.19▼$36.0052-Week Range$3.31▼$1,050.36Volume123,154 shsAverage Volume361,613 shsMarket Capitalization$7.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Aspire Biopharma Inc. is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions. The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis. In addition to epinephrine, Aspire has in-licensed a portfolio of novel PDE3/4 inhibitor compounds intended for maintenance therapy in chronic obstructive pulmonary disease (COPD) and severe asthma. Aspire’s development strategy emphasizes efficient clinical pathways and leveraging existing safety data to accelerate regulatory review. Founded in 2007 and headquartered in Henderson, Nevada, Aspire Biopharma serves the U.S. market while exploring international licensing and distribution opportunities. The company maintains partnerships with contract development and manufacturing organizations (CDMOs) to support scalable production of its inhalation devices and formulations. Aspire’s leadership team combines expertise in pharmaceutical R&D, regulatory affairs, and pulmonary device engineering to drive its product pipeline toward late-stage clinical and market readiness. Through strategic collaborations and targeted R&D investments, Aspire aims to address unmet medical needs in emergency medicine and chronic respiratory care. By focusing on inhaled delivery of both established and novel compounds, the company seeks to offer differentiated treatment options that improve patient outcomes and streamline acute care interventions.AI Generated. May Contain Errors. Read More Aspire Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreASBP MarketRank™: Aspire Biopharma scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAspire Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAspire Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Aspire Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Aspire Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aspire Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAspire Biopharma has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.23% of the float of Aspire Biopharma has been sold short.Short Interest Ratio / Days to CoverAspire Biopharma has a short interest ratio ("days to cover") of 0.11, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aspire Biopharma has recently decreased by 90.75%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAspire Biopharma does not currently pay a dividend.Dividend GrowthAspire Biopharma does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.72 News SentimentAspire Biopharma has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aspire Biopharma this week, compared to 2 articles on an average week.Search Interest13 people have searched for ASBP on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.MarketBeat Follows3 people have added Aspire Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aspire Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.80% of the stock of Aspire Biopharma is held by insiders.Percentage Held by Institutions19.17% of the stock of Aspire Biopharma is held by institutions.Read more about Aspire Biopharma's insider trading history. Receive ASBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aspire Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASBP Stock News HeadlinesAspire Biopharma’s BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of MembersMay 29 at 1:10 AM | usatoday.com10 Worst Performing NASDAQ Stocks So Far in 2026May 14, 2026 | insidermonkey.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 29 at 1:00 AM | Brownstone Research (Ad)Aspire Biopharma (ASBP) Authorizes $5M Share Repurchase ProgramMay 14, 2026 | finance.yahoo.comAspire Biopharma Holdings, Inc.: Aspire Biopharma Announces $5.0 Million Share Repurchase ProgramApril 27, 2026 | finanznachrichten.deASBP Stock Jumps 21% On Buyback Offer – Retail Believes Every Dip’s A Buying OpportunityApril 27, 2026 | msn.comLCID, ASBP, WLDS stocks hit 52-week lows: What drove the selloff?April 21, 2026 | msn.comASBP bulls back in control after 78% crash: What changed?April 21, 2026 | msn.comSee More Headlines ASBP Stock Analysis - Frequently Asked Questions How have ASBP shares performed this year? Aspire Biopharma's stock was trading at $158.28 on January 1st, 2026. Since then, ASBP stock has decreased by 96.6% and is now trading at $5.41. How were Aspire Biopharma's earnings last quarter? Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) released its earnings results on Friday, May, 15th. The company reported ($20.57) earnings per share for the quarter. The firm had revenue of $0.03 million for the quarter. When did Aspire Biopharma's stock split? Aspire Biopharma shares reverse split on the morning of Monday, May 11th 2026.The 1-30 reverse split was announced on Thursday, May 7th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 8th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Aspire Biopharma? Shares of ASBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2026Today5/29/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASBP Previous SymbolNASDAQ:PWUP CIK1847345 WebN/A Phone(561) 704-8527FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($116.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.48 million Net MarginsN/A Pretax Margin-34,333.49% Return on EquityN/A Return on Assets-398.04% Debt Debt-to-Equity RatioN/A Current Ratio2.26 Quick Ratio2.14 Sales & Book Value Annual Sales$10 thousand Price / Sales705.64 Cash FlowN/A Price / Cash FlowN/A Book Value$2.99 per share Price / Book1.82Miscellaneous Outstanding Shares1,300,000Free Float1,220,000Market Cap$7.06 million OptionableN/A Beta0.21 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ASBP) was last updated on 5/29/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aspire Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aspire Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
